Imunon (NASDAQ:IMNN) said its pivotal Phase III OVATION 3 trial of IMNN-001 in newly diagnosed advanced epithelial ovarian cancer is enrolling faster than its internal assumptions, while the company reported preliminary minimal residual disease findings and outlined its cash position following a June financing.
President and Chief Executive Officer Stacy Lindborg said the company’s central priority remains advancing IMNN-001, an IL-12-based therapy delivered through its TheraPlas platform, in combination with standard neoadjuvant and adjuvant chemotherapy. She described the second quarter as a period of continued clinical, operational and financial execution.
OVATION 3 Enrollment Exceeds Planning Assumptions
The company attributed the pace to investigator familiarity with IMNN-001, results from the earlier Phase II OVATION 2 study, a high rate of conversion from prescreening to randomization, and trial procedures designed not to delay standard-of-care treatment.
Faller said patient compliance with study visits and treatments has been strong and that electronic case report forms are being completed on schedule. A scheduled review by the independent data monitoring committee identified no new safety concerns, according to the company.
Imunon said it has 35% of its planned trial sites either active or in the activation process. Lindborg said the company has identified nearly twice as many prospective sites as needed to fill its planned site count.
Management said it continues to target the previously discussed enrollment timeline, though it did not provide a revised timeline. During the question-and-answer session, Lindborg said enrollment tends to be lower during the summer for ovarian cancer and other malignancies, but that current enrollment performance has continued to support the company’s confidence in its plan.
Phase II Data and MRD Study Findings
Imunon highlighted final results from the completed Phase II OVATION 2 study, which it said showed a 14.7-month improvement in median overall survival in the intention-to-treat population. Median overall survival was 45.1 months for patients receiving IMNN-001 versus 30.4 months for the control group, according to the company.
Among patients who received PARP inhibitor maintenance therapy, Imunon reported a 24.2-month difference in median overall survival, at 65.6 months versus 41.4 months. Faller said interim survival data from OVATION 2 were published in Gynecologic Oncology and presented at the 2025 American Society of Clinical Oncology annual meeting. The company expects to submit final overall-survival findings to a major medical conference for presentation in early 2027.
The company also discussed preliminary results from an ongoing Phase II minimal residual disease, or MRD, study being conducted with Break Through Cancer and led by investigators at The University of Texas MD Anderson Cancer Center.
- Among patients reaching second-look laparoscopy, MRD positivity was 44% in the IMNN-001 arm and 67% in the control arm.
- Circulating tumor DNA clearance was 87.5% in the IMNN-001 arm, compared with 62% in the control arm.
- No evidence of disease following frontline therapy was reported in 100% of patients in the IMNN-001 arm, compared with 56% in the control arm.
Management cautioned that the findings came from a small preliminary cohort and that the study was not sized based on statistical power. Faller said the trial remains ongoing and may or may not reach statistical significance as enrollment and assessments continue.
Lindborg said the company expects and hopes the MRD study will reach full enrollment by the end of 2026, followed by the observation period needed for second-look laparoscopy. Imunon said it plans to publish the MRD data and is discussing the timing of presentations with the study’s principal investigator.
The company said the MRD trial has also established that IMNN-001 can be administered with bevacizumab and that patients are receiving the therapy in the maintenance setting. The Gynecologic Oncology Group is not formally involved in the MRD study, though Imunon said it has received strategic input from the group on its Phase III program.
Safety, Translational Research and Upcoming Events
Imunon said no cytokine release syndrome, systemic toxicities or serious immune-related adverse events have been observed in the MRD study or, to date, in OVATION 3. The company said its translational analyses have shown IL-12 expression in macrophages, downstream interferon-gamma activity, and evidence of macrophage and T-cell activation.
Faller said the company was invited to present its TheraPlas technology at the inaugural American Association for Cancer Research Drug Discovery and Development Congress in July. Additional translational data have been accepted for presentation at the Society for Immunotherapy of Cancer conference in November 2026.
Imunon plans to hold an R&D Day in New York on Sept. 23. Management said it expects to provide a deeper review of IMNN-001 and its development plans, but does not expect to have circulating tumor DNA data from OVATION 3 available for discussion at that event.
Second-Quarter Financial Results
For the second quarter, Imunon reported research and development expense of $1.5 million, up from $1.2 million in the prior-year period, primarily due to clinical and manufacturing costs associated with OVATION 3.
General and administrative expense fell about 20% to $1.3 million from $1.6 million a year earlier. Net cash used in operating activities was $3.0 million during the quarter, down from $4.0 million in the first quarter of 2026.
As of June 30, Imunon had $6.9 million in cash and cash equivalents. The company completed a financing of up to $10 million in June consisting of non-redeemable, non-convertible preferred stock and secured promissory notes. Lindborg said the transaction included no warrants.
Chief Financial Officer Josh Blacher said available cash, the June financing and cost-discipline measures were expected to support operations through the end of 2026. Lindborg added that Imunon will need additional capital to complete the Phase III trial and support general and administrative expenses.
About Imunon (NASDAQ:IMNN)
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
